Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer Clinical Trial

— LuCAB  

Official title:

Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05340374
• Other study ID #: 21/018
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: July 14, 2022
• Est. completion date: December 2026

Study information

• Verified date: November 2023
• Source: Peter MacCallum Cancer Centre, Australia
• Contact: Gaurav Sharma
• Phone: 03 85596830
• Email: Gaurav.Sharma[@]petermac.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical trial will evaluate the safety of Cabazitaxel in combination with 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer.

Description:

This prospective, single-centre, single-arm, open label, phase I/II trial will assess the safety, efficacy and anti-tumour activity of cabazitaxel in combination with 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC).

This study aims to assess and establish the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended phase 2 dose (RP2D) of cabazitaxel in combination with 177Lu-PSMA-617 in patients with mCRPC.

32-44 men with mCRPC who have progressed on prior docetaxel and a second-generation AR antagonist will be enrolled in this trial in two stages: dose escalation and a dose expansion phase over a period of 18 months.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 44
• Est. completion date: December 2026
• Est. primary completion date: June 20, 2026
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male patients aged 18 years or older at the time of informed consent.

2. Patient has provided written informed consent.

3. Histologically confirmed adenocarcinoma of the prostate without neuroendocrine or small cell differentiation.

4. Eastern Cooperative Oncology Group (ECOG) performance status of = 1

5. Patients must have had prior treatment with docetaxel.

6. Patients must have progressed on a second-generation androgen receptor (AR)-targeted agent (e.g., enzalutamide, abiraterone, or apalutamide) in the castrate-resistant setting.

7. Patients must have progressive disease. The Prostate Cancer Clinical Trials Working Group 3 (PCWG3) defines this as any one of the following:

1. PSA progression: minimum of two rising PSA values from a baseline measurement with an interval of = 1 week between each measurement

2. Soft tissue or visceral disease progression as per Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) criteria

3. Bone progression: = 2 new lesions on bone scan

8. At least three weeks since the completion of surgery prior to registration.

9. Prior surgical orchiectomy or chemical castration maintained on luteinizing hormone-releasing hormone (LHRH) analogue (agonist or antagonist).

10. Serum testosterone levels = 1.75nmol/L within 28 days prior to registration.

11. Imaging evidence of metastatic disease documented with either whole body bone scan (WBBS) or computed tomography (CT) scan performed within 28 days prior to registration.

12. Significant prostate-specific membrane antigen (PSMA) avidity on PSMA PET/CT, defined as a minimum uptake of SUVmax 15 at a site of disease.

13. Patients must have a life expectancy = 12 weeks.

14. Assessed by a medical oncologist as suitable for treatment with cabazitaxel and 177Lu-PSMA-617.

15. Patients must have adequate bone marrow, hepatic and renal function documented within 28 days prior to registration, defined as:

1. Haemoglobin = 90 g/L independent of transfusions (no red blood cell transfusion in last 28 days prior to registration)

2. Absolute neutrophil count (ANC) = 1.5x10^9/L

3. Platelets = 150 x10^9/L

4. Total bilirubin = 1.5 x upper limit of normal (ULN) except for patients with known Gilbert's syndrome, where this applies for the unconjugated bilirubin component

5. Aspartate transaminase (AST) and alanine transaminase (ALT) = 2.5 x ULN if there is no evidence of liver metastasis or = 5 x ULN in the presence of liver metastases

6. Albumin = 25 g/L

7. Adequate renal function: patients must have a creatinine clearance estimated of = 40 mL/min using the Cockcroft-Gault equation

16. Sexually active patients are willing to use medically acceptable forms of barrier contraception.

17. Willing and able to comply with all study requirements, including all treatments and the timing and nature of all required assessments.

Exclusion Criteria:

1. Superscan on WBBS or diffuse marrow disease on PSMA PET.

2. Site(s) of measurable disease that are FDG-positive with low PSMA expression (SUVmax <10).

3. Prior treatment with cabazitaxel or 177Lu-PSMA-617.

4. Contraindications to the use of corticosteroid treatment.

5. Other malignancies within the previous 2-years other than basal cell or squamous cell carcinomas of skin or other cancers that are unlikely to recur within 24 months.

6. Presence of untreated brain metastases or leptomeningeal metastases.

7. Patients with symptomatic or impending cord compression unless appropriately treated beforehand and clinically stable for = four weeks.

8. Concurrent illness, including severe infection that may jeopardise the ability of the patient to undergo the procedures outlined in this protocol with reasonable safety.

9. Persistent toxicities (CTCAE v5.0 >/= Grade 2) caused by previous cancer therapy, excluding alopecia.

10. Known HIV or hepatitis B or C infection.

11. Radiotherapy or systemic anti-cancer therapies administered within 14 days prior to registration, excluding androgen deprivation therapy (ADT).

Related Conditions & MeSH terms

• mCRPC
• Metastatic Castration-resistant Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Cabazitaxel
Cabazitaxel belongs to the Taxane group of drugs which function by interfering with microtubule depolymerisation and thus inhibit mitosis, which leads to cell death via apoptosis. It is the first chemotherapy agent to improve survival in patients with mCRPC with progressive disease after docetaxel-based treatment.
• 177Lu-PSMA-617
Lutetium-177 (177Lu)-PSMA is a radiopharmaceutical comprised of a small molecule inhibitor of PSMA that binds with high affinity to PSMA which is expressed on the prostate cancer cell, labelled with 177Lu. 177Lu has favourable characteristics for radionuclide therapy emitting both a short-range (1-2mm) cytotoxic beta-particle, minimising irradiation of non-targeted normal tissues, alongside gamma emission that allows imaging. Multiple clinical trials have demonstrated high clinical activity and limited normal tissue toxicity using 177Lu-PSMA-617.

Locations

Country	Name	City	State
Australia	Peter MacCallum Cancer Centre	Melbourne	Victoria

Sponsors (1)

Lead Sponsor	Collaborator
Peter MacCallum Cancer Centre, Australia

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with Dose Limiting Toxicities (DLTs)	A DLT is defined as a toxicity that prevents further administration of the trial treatment at that dose level.; Each cohort of 3 patients be assessed for DLTs in the first 6 weeks (cycle 1) of treatment and a dose for the next cohort will be determined.	Dose escalation phase is expected to be completed 9 months from the time the first patient is recruited.
Primary	Maximum Tolerated dose (MTD)	The MTD is defined as the highest dose level at which the incidence of DLT was less than 2/6.	Dose escalation phase is expected to be completed 9 months from the time the first patient is recruited.
Primary	Recommended Phase 2 Dose (RP2D)	After the MTD is established, additional patients will be treated at the MTD. Safety and efficacy data from the study will be used to define the RP2D.	Up to 30 months from the time the first patient is recruited.
Secondary	Adverse Events (AEs) and Serious Adverse Events (SAEs) measured using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0	Safety of the combination will be measured by AEs and SAEs.	Through study completion, up until 24 months after the last patient commences treatment
Secondary	50% Prostate-Specific Antigen Response Rate (PSA-RR)	PSA will be assessed at baseline and every 3 weeks from cycle 1 day 1. PSA response will be defined as a 50% or greater decrease in PSA from baseline to the lowest post-baseline PSA result. A second consecutive value obtained 3 or more weeks later is required to confirm the PSA response.	Through study completion, up until 24 months after the last patient commences treatment
Secondary	Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST1.1) in patients with measurable disease	Objective Response (OR) is only applicable for the subset of patients with measurable disease by RECIST1.1. OR is defined as a partial response (PR) or complete response (CR) at any stage from time of commencement of protocol treatment to the time of subsequent systemic anti-cancer treatment. The ORR is calculated as the proportion of patients with a best response of CR or PR.	Through study completion, up until 24 months after the last patient commences treatment
Secondary	Radiographic Progression-Free Survival (rPFS)	rPFS is defined as the time from treatment initiation to the first date of documented radiographic progression using conventional imaging or death due to any cause, whichever occurs first. The radiographic progression will be assessed by the investigator per RECIST1.1 for soft tissue and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) for bone lesions.	Through study completion, up until 24 months after the last patient commences treatment
Secondary	PSA progression free survival (PSA-PFS)	PSA-PFS is defined as the time from treatment initiation to the date of PSA progression per PCWG3 or death due to any cause, whichever occurs first. The date of PSA progression is the date that an increase of 25% or more and an absolute increase of 2ng/mL or more from the nadir is documented. For patients who have an initial PSA decline during treatment, this must be confirmed by a second value 3 or more weeks later.	Through study completion, up until 24 months after the last patient commences treatment
Secondary	Overall survival (OS)	OS is defined as the time from treatment initiation to the date of death due to any cause.	Through study completion, up until 24 months after the last patient commences treatment
Secondary	Describe pain within 12 months of treatment commencement	Pain will be assessed using the Brief Pain Inventory - Short Form (BPI-SF). This form assesses pain at its "worst," "least," "average," and "now" (current pain) in a 24-hour period at different timepoints, using a scale from 0-10. A higher score indicates more severe pain. The primary endpoint is the area under the curve (AUC) obtained from repeated patient responses to the BPI-SF item concerning "worst pain" in 24 hours.; Pain will be assessed at baseline, 6 weeks, 3 months, 6 months, 9 months and 12 months and will be scored according to the respective manuals.	Through completion of 12 months after treatment commencement of last patient
Secondary	Describe health-related quality of life (QoL) within 12 months of treatment commencement	QoL will be assessed using the Functional Assessment of Cancer Therapy for Prostate Cancer (FACT-P) questionnaire. The primary endpoint for QoL is the area under the curve (AUC) of the trial outcome index (TOI), which is the sum of the Functional Assessment of Cancer Therapy -General (FACT-G), physical well-being, functional well-being, and prostate cancer subscale (PCS) scores. The score ranges from 0-156. A higher score indicates better quality of life.; QoL will be assessed at baseline, 6 weeks, 3 months, 6 months, 9 months and 12 months and will be scored according to the respective manuals.	Through completion of 12 months after treatment commencement of last patient
Secondary	Rate of treatment discontinuation due to toxicity	The percentage of patients who discontinue treatment due to treatment related toxicity will be reported.	Through study completion, up until 24 months after the last patient commences treatment